Feature | March 05, 2014

Carotid Artery MRI Helps Predict Strokes, Heart Attacks

Carotid Artery MRI Systems Clinical Study Trial Cath Lab Cardiac Diagnostics

This shows transverse gadolinium-enhanced T1-weighted MR images obtained superior to the carotid artery bifurcation in a 72-year-old man. L = ICA lumen. (a) Low-signal-intensity calcium (arrow) and lipid core (arrowheads) can be seen. (b) Note contouring of the ICA. The outer adventitial wall (red), lipid core (blue), calcification (green), and vessel lumen (purple) are visible.Credit: Radiological Society of North America

March 5, 2014 — Noninvasive imaging of carotid artery plaque with magnetic resonance imaging (MRI) can accurately predict future cardiovascular events like strokes and heart attacks in people without a history of cardiovascular disease, according to a study published online in the journal Radiology.


Researchers have long known that some arterial plaque is more dangerous because of its vulnerability to rupture. MRI can discern features of vulnerable plaque, such as a lipid core with a thin fibrous cap. This ability makes MRI a potentially valuable tool for identifying patients at risk for subsequent cardiovascular events.


To study the predictive value of MRI plaque imaging, researchers performed carotid artery ultrasound and MRI on 946 asymptomatic patients from the Multi-Ethnic Study of Atherosclerosis (MESA). 


The researchers used ultrasound to assess carotid wall thickness and MRI to define carotid plaque composition and the remodeling index, a measure of changes in vessel size. Imaging results were compared with cardiovascular events, including heart attacks, stroke and death, for an average of 5.5 years after examination. 


“We studied asymptomatic individuals with a low risk of cardiovascular events at baseline and used noninvasive imaging to predict the risk of an event downstream,” said David A. Bluemke, M.D, Ph.D., from the National Institutes of Health Clinical Center in Bethesda, Md.


Cardiovascular events occurred in 59 of the patients. Abnormal thickening of the carotid artery wall and the presence of a lipid core and calcium in the internal carotid artery on MRI were significant predictors of subsequent events. A lipid core was present in almost half of the patients who had an event, compared with only 17.8 percent of those who did not have an event.


“The primary factors that predicted future risk were measures of vessel wall thickness in combination with the presence or absence of a lipid core,” Bluemke said. “The presence of a lipid core was 50 percent more common in people who had subsequent events.”


Use of MRI improved the reclassification of baseline cardiovascular risk in the study group. When both the carotid remodeling index and lipid core were used for risk stratification, approximately 16 percent more patients with events and 7 percent without events were correctly reclassified compared with the use of traditional risk factors.


“The results bolster the use of MRI as a surrogate marker of efficacy in therapeutic studies and point to a role in determining which patients might need more aggressive treatments,” Bluemke said. “As risk factor prediction gets better, we’ll be able to screen more intelligently and use more intensive treatments in those individuals who face a higher risk of cardiovascular events.”


Bluemke said sequences for plaque composition could be readily added to existing carotid MRI angiography protocols for clinical purposes.


“Carotid MRI has significant advantages,” he said. “The results are more reproducible than those of ultrasound.”


Availability and cost effectiveness could limit the use of MRI, Bluemke said. However, ultrasound and computed tomography (CT) are viable alternatives for screening, he said, especially with improvements in CT dose reduction.


For more information: radiology.org


Related Content

triple therapy, dual antiplatelet therapy, atrial fibrillation, heart attack, older patients, JACC
News | Antiplatelet and Anticoagulation Therapies| August 04, 2015
Triple therapy is no better than dual antiplatelet therapy in preventing major adverse cardiac events in older patients...
MRI, cardiovascular risk factors, Alzheimer's disease, early predictors
News | Cardiac Imaging| August 04, 2015
Specific cardiovascular risk factors are associated with smaller regional brain volumes that may be early indicators of...
Sunshine Heart, C-Pulse, circulatory support system, update
News | Heart Failure| August 03, 2015
Sunshine Heart announced plans to commence a first-in-human study using its novel C-Pulse transcutaneous energy...
Biotronik, CE approval, 3T MRI scanning, pacemakers, ICDs
News | Implantable Cardioverter Defibrillators (ICD)| August 03, 2015
Biotronik announced CE approval of 3 Tesla (T) magnetic resonance imaging (MRI) scanning with exclusion zone for its...
Pie Medical Imaging, CAAS IntraVascular 2.0, OCT, IVUS, NIRS-IVUS
Technology | Intravascular Imaging| August 03, 2015
Pie Medical Imaging announced the release of CAAS IntraVascular 2.0, the dedicated software for analysis of...
Products | Intravascular Imaging| August 03, 2015
European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

Feature | Stents| July 31, 2015
According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents...
Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
Hansen Medical, Magellan 10 French Robotic Catheter, FDA 510(k) clearance
Technology | Robotic Systems| July 29, 2015
The Magellan 10 French Robotic Catheter from Hansen Medical is indicated for use in the peripheral vasculature.
MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
Overlay Init